{"id":6102,"date":"2022-11-20T23:21:59","date_gmt":"2022-11-20T23:21:59","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=6102"},"modified":"2023-08-29T17:56:16","modified_gmt":"2023-08-29T17:56:16","slug":"invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=6102","title":{"rendered":"Invex Therapeutics \u62db\u52df\u9996\u4f4d\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u60a3\u8005\u8fdb\u884c Presendin \u8bd5\u9a8c"},"content":{"rendered":"

\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u5c06\u9996\u4f8b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u968f\u673a\u5206\u914d\u5230\u5176\u4f7f\u7528\u5148\u5bfc\u836f\u7269 Presendin \u7684 IIH Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u3002<\/p>\n

\u8be5\u60a3\u8005\u662f\u5728\u5357\u6fb3\u5927\u5229\u4e9a\u7684 VisionSA \u62db\u52df\u7684\uff0c\u6b64\u540e\u5176\u4ed6\u4e34\u5e8a\u8bd5\u9a8c\u5730\u70b9\u5728\u6fb3\u5927\u5229\u4e9a\u548c\u82f1\u56fd\u53d8\u5f97\u6d3b\u8dc3\u5e76\u5f00\u653e\u62db\u52df\u3002<\/p>\n

\u975e\u6267\u884c\u4e3b\u5e2d Jason Loveridge \u535a\u58eb\u8868\u793a\uff0c\u8fd9\u5bf9\u516c\u53f8\u548c IIH \u60a3\u8005\u6765\u8bf4\u662f\u4e00\u4e2a\u91cd\u8981\u7684\u91cc\u7a0b\u7891\u3002<\/p>\n

\u201c\u9274\u4e8e\u6211\u4eec\u8fc4\u4eca\u4e3a\u6b62\u53d6\u5f97\u7684\u6210\u679c\uff0c\u6211\u4eec\u76f8\u4fe1 Presendin \u6709\u53ef\u80fd\u4ee5\u5b89\u5168\u6709\u6548\u7684\u65b9\u5f0f\u6539\u5584 IIH \u60a3\u8005\u7684\u4e34\u5e8a\u7ed3\u679c\u548c\u751f\u6d3b\u8d28\u91cf\uff0c\u800c\u76ee\u524d\u7684\u6cbb\u7597\u65b9\u6cd5\u4ecd\u7136\u7f3a\u4e4f\uff0c\u201d\u4ed6\u8bf4\u3002<\/p>\n

\u5173\u4e8e\u4e34\u5e8a\u8bd5\u9a8c<\/h2>\n

Evolve \u662f\u4e00\u9879\u5b89\u6170\u5242\u5bf9\u7167\u7684\u53cc\u76f2\u8bd5\u9a8c\uff0c\u5c06\u968f\u673a\u5206\u914d 240 \u540d\u65b0\u8bca\u65ad\u7684 IIH \u60a3\u8005\uff0c\u4ee5\u786e\u5b9a Presendin \u4e0e\u5b89\u6170\u5242\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\uff0c\u5728\u516d\u4e2a\u6708\u7684\u65f6\u95f4\u5185\u6bcf\u5468\u7ed9\u836f\u4e00\u6b21\u3002<\/p>\n

\u8be5\u8bd5\u9a8c\u7684\u4e3b\u8981\u7ec8\u70b9\u662f\u9885\u5185\u538b\u76f8\u5bf9\u4e8e\u57fa\u7ebf\u7684\u53d8\u5316\uff0c\u5173\u952e\u7684\u6b21\u8981\u7ec8\u70b9\u4e0e\u89c6\u529b\u548c\u5934\u75db\u7ed3\u679c\u6d4b\u91cf\u6709\u5173\u3002<\/p>\n

Invex \u6253\u7b97\u5728\u5168\u7403\u5f00\u8bbe\u591a\u8fbe 40 \u4e2a\u4e34\u5e8a\u7ad9\u70b9\u3002<\/p>\n

Loveridge \u535a\u58eb\u8868\u793a\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u6ee1\u8db3 Presendin \u5728\u6b27\u76df\u3001\u82f1\u56fd\u548c\u6fb3\u5927\u5229\u4e9a\u4e0a\u5e02\u6279\u51c6\u7528\u4e8e\u6cbb\u7597 IIH \u7684\u8981\u6c42\u3002<\/p>\n

\u5fae\u7403\u914d\u65b9<\/h2>\n

Presendin \u662f\u4e00\u79cd\u6bcf\u5468\u4e00\u6b21\u7684\u76ae\u4e0b\u7f13\u91ca\u827e\u585e\u90a3\u80bd\u5fae\u7403\u5236\u5242\uff0c\u6700\u521d\u7531\u97e9\u56fd\u751f\u7269\u5236\u836f\u516c\u53f8 Peptron Inc \u5f00\u53d1\uff0c\u8be5\u516c\u53f8\u5f00\u53d1\u5177\u6709\u9ad8\u6280\u672f\u58c1\u5792\u7684\u7f13\u91ca\u80bd\u7c7b\u836f\u7269\uff0c\u7528\u4e8e\u6cbb\u7597\u5371\u53ca\u751f\u547d\u7684\u6162\u6027\u75be\u75c5\u3002<\/p>\n

2021 \u5e74 9 \u6708\uff0cInvex \u4e0e Peptron \u5c31 IIH \u7684 Presendin \u7b7e\u8ba2\u4e86\u72ec\u5bb6\u5408\u4f5c\u3001\u5236\u9020\u548c\u4f9b\u5e94\u534f\u8bae<\/a>\uff0c\u9762\u5411\u9664\u97e9\u56fd\u4ee5\u5916\u7684\u6240\u6709\u4e3b\u8981\u5e02\u573a\u3002<\/p>\n

Exenatide\u662f\u4e00\u79cd\u5c0f\u80bd\uff0c\u662f GLP-1 \u6fc0\u52a8\u5242 exendin-4 \u7684\u5408\u6210\u7248\u672c\uff0c\u76ee\u524d\u5df2\u83b7\u51c6\u7528\u4e8e\u6cbb\u7597 2 \u578b\u7cd6\u5c3f\u75c5\u3002<\/p>\n

2017 \u5e74\uff0cInvex \u5728 IIH \u4e2d\u83b7\u5f97\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u548c\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\u6388\u4e88\u7684\u827e\u585e\u90a3\u80bd\u5b64\u513f\u836f\u79f0\u53f7\u3002<\/p>\n

\u7981\u7528\u5934\u75db<\/h2>\n

IIH \u7684\u7279\u70b9\u662f\u9885\u5185\u538b\u4e25\u91cd\u5347\u9ad8\uff0c\u5bfc\u81f4\u6bcf\u5929\u5934\u75db\u5e76\u538b\u8feb\u89c6\u795e\u7ecf\u3002<\/p>\n

\u901a\u5e38\u53d1\u75c5\u5e74\u9f84\u5728 30 \u5c81\u5de6\u53f3\uff0c\u8fd9\u79cd\u60c5\u51b5\u5728\u80a5\u80d6\u5973\u6027\u4e2d\u6700\u5e38\u89c1\u3002<\/p>\n

IIH \u662f\u4e00\u79cd\u5feb\u901f\u589e\u957f\u7684\u5b64\u513f\u9002\u5e94\u75c7\uff0c\u5176\u53d1\u75c5\u7387\u5728\u8fc7\u53bb 10 \u5e74\u4e2d\u589e\u52a0\u4e86 350% \u4ee5\u4e0a\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"

\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u5c06\u9996\u4f8b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u968f\u673a\u5206\u914d\u5230\u5176\u4f7f\u7528\u5148\u5bfc\u836f\u7269 Presendin \u7684 IIH Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u3002 \u8be5\u60a3\u8005\u662f\u5728\u5357\u6fb3\u5927\u5229\u4e9a\u7684 VisionSA \u62db\u52df\u7684\uff0c\u6b64\u540e\u5176\u4ed6\u4e34\u5e8a\u8bd5\u9a8c\u5730\u70b9\u5728\u6fb3\u5927\u5229\u4e9a\u548c\u82f1\u56fd\u53d8\u5f97\u6d3b\u8dc3\u5e76\u5f00\u653e\u62db\u52df\u3002 \u975e\u6267\u884c\u4e3b\u5e2d Jason Loveridge \u535a\u58eb\u8868\u793a\uff0c\u8fd9\u5bf9\u516c\u53f8\u548c IIH \u60a3\u8005\u6765\u8bf4\u662f\u4e00\u4e2a\u91cd\u8981\u7684\u91cc\u7a0b\u7891\u3002 \u201c\u9274\u4e8e\u6211\u4eec\u8fc4\u4eca\u4e3a\u6b62\u53d6\u5f97\u7684\u6210\u679c\uff0c\u6211\u4eec\u76f8\u4fe1 Presendin \u6709\u53ef\u80fd\u4ee5\u5b89\u5168\u6709\u6548\u7684\u65b9\u5f0f\u6539\u5584 IIH \u60a3\u8005\u7684\u4e34\u5e8a\u7ed3\u679c\u548c\u751f\u6d3b\u8d28\u91cf\uff0c\u800c\u76ee\u524d\u7684\u6cbb\u7597\u65b9\u6cd5\u4ecd\u7136\u7f3a\u4e4f\uff0c\u201d\u4ed6\u8bf4\u3002 \u5173\u4e8e\u4e34\u5e8a\u8bd5\u9a8c Evolve \u662f\u4e00\u9879\u5b89\u6170\u5242\u5bf9\u7167\u7684\u53cc\u76f2\u8bd5\u9a8c\uff0c\u5c06\u968f\u673a\u5206\u914d 240 \u540d\u65b0\u8bca\u65ad\u7684 IIH \u60a3\u8005\uff0c\u4ee5\u786e\u5b9a Presendin \u4e0e\u5b89\u6170\u5242\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\uff0c\u5728\u516d\u4e2a\u6708\u7684\u65f6\u95f4\u5185\u6bcf\u5468\u7ed9\u836f\u4e00\u6b21\u3002 \u8be5\u8bd5\u9a8c\u7684\u4e3b\u8981\u7ec8\u70b9\u662f\u9885\u5185\u538b\u76f8\u5bf9\u4e8e\u57fa\u7ebf\u7684\u53d8\u5316\uff0c\u5173\u952e\u7684\u6b21\u8981\u7ec8\u70b9\u4e0e\u89c6\u529b\u548c\u5934\u75db\u7ed3\u679c\u6d4b\u91cf\u6709\u5173\u3002 Invex \u6253\u7b97\u5728\u5168\u7403\u5f00\u8bbe\u591a\u8fbe 40 \u4e2a\u4e34\u5e8a\u7ad9\u70b9\u3002 Loveridge \u535a\u58eb\u8868\u793a\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u6ee1\u8db3 Presendin \u5728\u6b27\u76df\u3001\u82f1\u56fd\u548c\u6fb3\u5927\u5229\u4e9a\u4e0a\u5e02\u6279\u51c6\u7528\u4e8e\u6cbb\u7597 IIH \u7684\u8981\u6c42\u3002 \u5fae\u7403\u914d\u65b9 Presendin \u662f\u4e00\u79cd\u6bcf\u5468\u4e00\u6b21\u7684\u76ae\u4e0b\u7f13\u91ca\u827e\u585e\u90a3\u80bd\u5fae\u7403\u5236\u5242\uff0c\u6700\u521d\u7531\u97e9\u56fd\u751f\u7269\u5236\u836f\u516c\u53f8 Peptron Inc \u5f00\u53d1\uff0c\u8be5\u516c\u53f8\u5f00\u53d1\u5177\u6709\u9ad8\u6280\u672f\u58c1\u5792\u7684\u7f13\u91ca\u80bd\u7c7b\u836f\u7269\uff0c\u7528\u4e8e\u6cbb\u7597\u5371\u53ca\u751f\u547d\u7684\u6162\u6027\u75be\u75c5\u3002 2021… Continue reading Invex Therapeutics \u62db\u52df\u9996\u4f4d\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u60a3\u8005\u8fdb\u884c Presendin \u8bd5\u9a8c<\/span><\/a><\/p>\n","protected":false},"author":4,"featured_media":18658,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"\nInvex Therapeutics \u62db\u52df\u9996\u4f4d\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u60a3\u8005\u8fdb\u884c Presendin \u8bd5\u9a8c<\/title>\n<meta name=\"description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u5c06\u9996\u4f8b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u968f\u673a\u5206\u914d\u5230\u5176\u4f7f\u7528\u5148\u5bfc\u836f\u7269 Presendin \u7684 IIH Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics \u62db\u52df\u9996\u4f4d\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u60a3\u8005\u8fdb\u884c Presendin \u8bd5\u9a8c\" \/>\n<meta property=\"og:description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u5c06\u9996\u4f8b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u968f\u673a\u5206\u914d\u5230\u5176\u4f7f\u7528\u5148\u5bfc\u836f\u7269 Presendin \u7684 IIH Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-20T23:21:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:56:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-Presendin-2021-2022-manufacturing-tax-rebate-research-development-IIH-EVOLVE-clinical-trial.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Imelda Cotton\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Imelda Cotton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial\/\",\"name\":\"Invex Therapeutics \u62db\u52df\u9996\u4f4d\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u60a3\u8005\u8fdb\u884c Presendin \u8bd5\u9a8c\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-11-20T23:21:59+00:00\",\"dateModified\":\"2023-08-29T17:56:16+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\"},\"description\":\"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u5c06\u9996\u4f8b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u968f\u673a\u5206\u914d\u5230\u5176\u4f7f\u7528\u5148\u5bfc\u836f\u7269 Presendin \u7684 IIH Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics \u62db\u52df\u9996\u4f4d\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u60a3\u8005\u8fdb\u884c Presendin \u8bd5\u9a8c\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\",\"name\":\"Imelda Cotton\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"caption\":\"Imelda Cotton\"},\"description\":\"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics \u62db\u52df\u9996\u4f4d\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u60a3\u8005\u8fdb\u884c Presendin \u8bd5\u9a8c","description":"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u5c06\u9996\u4f8b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u968f\u673a\u5206\u914d\u5230\u5176\u4f7f\u7528\u5148\u5bfc\u836f\u7269 Presendin \u7684 IIH Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics \u62db\u52df\u9996\u4f4d\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u60a3\u8005\u8fdb\u884c Presendin \u8bd5\u9a8c","og_description":"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u5c06\u9996\u4f8b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u968f\u673a\u5206\u914d\u5230\u5176\u4f7f\u7528\u5148\u5bfc\u836f\u7269 Presendin \u7684 IIH Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial\/","og_site_name":"smallcapsCN","article_published_time":"2022-11-20T23:21:59+00:00","article_modified_time":"2023-08-29T17:56:16+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-Presendin-2021-2022-manufacturing-tax-rebate-research-development-IIH-EVOLVE-clinical-trial.jpg","type":"image\/jpeg"}],"author":"Imelda Cotton","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Imelda Cotton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial\/","name":"Invex Therapeutics \u62db\u52df\u9996\u4f4d\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u60a3\u8005\u8fdb\u884c Presendin \u8bd5\u9a8c","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-11-20T23:21:59+00:00","dateModified":"2023-08-29T17:56:16+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e"},"description":"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u5c06\u9996\u4f8b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u968f\u673a\u5206\u914d\u5230\u5176\u4f7f\u7528\u5148\u5bfc\u836f\u7269 Presendin \u7684 IIH Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics \u62db\u52df\u9996\u4f4d\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u60a3\u8005\u8fdb\u884c Presendin \u8bd5\u9a8c"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e","name":"Imelda Cotton","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","caption":"Imelda Cotton"},"description":"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.","url":"https:\/\/smallcapscn.x5view.co\/?author=4"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6102"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6102"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6102\/revisions"}],"predecessor-version":[{"id":15981,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6102\/revisions\/15981"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/18658"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}